doi: 10.1161/hs0202.102332
(Stroke. 2002;33:572.)
© 2002 American Heart Association, Inc.
Original Contributions |
Effect of Controlled Release/Extended Release Metoprolol on Carotid Intima-Media Thickness in Patients With Hypercholesterolemia
A 3-Year Randomized Study
From the Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska University Hospital/Sahlgrenska (O.W., J.H., J.W., C.S., G.B.), and the Department of Medical Chemistry, Göteborg University (S-O.O.), Gothenburg; and AstraZeneca (J.W.), Mölndal, Sweden.
Correspondence to Johannes Hulthe, MD, PhD, Wallenberg Laboratory, Sahlgrenska University/Sahlgrenska, SE 413 45 Gothenburg, Sweden. E-mail johannes{at}wlab.gu.se
Background and Purpose— ß-Adrenergic blockade has in several studies been shown to improve survival after myocardial infarction. In animal experiments ß-blockers have also shown an antiatherosclerotic effect. The aim of this study was to test the hypothesis that the ß-blocker metoprolol succinate controlled release/extended release (CR/XL), when given to patients with hypercholesterolemia on concomitant lipid-lowering therapy, provides an additional antiatherosclerotic effect to that provided by the statins, measured as carotid intima-media thickness (IMT).
Methods— We conducted a randomized, double-blind, placebo-controlled, single center trial to compare the effect of metoprolol CR/XL (100 mg once daily) and placebo on the progression of carotid IMT during 36 months of treatment in patients with hypercholesterolemia and signs of early atherosclerosis in the carotid artery. Most patients were prescribed lipid-lowering treatment with statins.
Results— A highly significant difference in the progression rate of the composite variable of carotid bulb IMT+common carotid IMT was observed between the metoprolol CR/XL and placebo groups after 1 year of treatment (-0.08 versus -0.01 mm; P=0.004), an effect that was sustained after 3 years of follow-up (-0.06 versus +0.03 mm; P=0.011). The patients had high levels of total cholesterol at randomization: 9.4 mmol/L in the metoprolol CR/XL group and 8.6 mmol/L in the placebo group. During the study the 2 randomization groups were treated with lipid-lowering drugs, mainly statins, to a similar extent, and total cholesterol was reduced to 6.4 mmol/L at end of follow-up in both groups.
Conclusions— The results from the present study in patients with hypercholesterolemia under concomitant lipid-lowering therapy are the first clinical data to show an antiatherosclerotic effect of ß-blockade as additional therapy to statins. The data indicate that statin treatment and treatment with ß-blockers affect different mechanisms in the atherosclerotic process and have additive beneficial effects.
Key Words: antilipemic agents • atherosclerosis • ß blockade • ultrasonography
This article has been cited by other articles:
 |
|
 |
|
  B. A. Kaufmann Ultrasound molecular imaging of atherosclerosis Cardiovasc Res, September 1, 2009; 83(4): 617 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Sipahi, E. M. Tuzcu, K. E. Wolski, S. J. Nicholls, P. Schoenhagen, B. Hu, C. Balog, M. Shishehbor, W. A. Magyar, T. D. Crowe, et al. {beta}-Blockers and Progression of Coronary Atherosclerosis: Pooled Analysis of 4 Intravascular Ultrasonography Trials Ann Intern Med, July 3, 2007; 147(1): 10 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Tsivgoulis, K. Spengos, and N. Zakopoulos Response to Letter by Talelli and Ellul Stroke, November 1, 2006; 37(11): 2656 - 2656. [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Crouse III Thematic review series: Patient-Oriented Research. Imaging atherosclerosis: state of the art J. Lipid Res., August 1, 2006; 47(8): 1677 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Tsivgoulis, K. Vemmos, C. Papamichael, K. Spengos, E. Manios, K. Stamatelopoulos, D. Vassilopoulos, and N. Zakopoulos Common Carotid Artery Intima-Media Thickness and the Risk of Stroke Recurrence Stroke, July 1, 2006; 37(7): 1913 - 1916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-G. Wang, J. A. Staessen, Y. Li, L. M. Van Bortel, T. Nawrot, R. Fagard, F. H. Messerli, and M. Safar Carotid Intima-Media Thickness and Antihypertensive Treatment: A Meta-Analysis of Randomized Controlled Trials Stroke, July 1, 2006; 37(7): 1933 - 1940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Tardif, T. Heinonen, D. Orloff, and P. Libby Vascular Biomarkers and Surrogates in Cardiovascular Disease Circulation, June 27, 2006; 113(25): 2936 - 2942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Go, C. Iribarren, M. Chandra, P. V. Lathon, S. P. Fortmann, T. Quertermous, M. A. Hlatky, and for the Atherosclerotic Disease, Vascular Function Statin and beta-blocker therapy and the initial presentation of coronary heart disease. Ann Intern Med, February 21, 2006; 144(4): 229 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Raggi, A. Taylor, Z. Fayad, D. O'Leary, S. Nissen, D. Rader, and L. J. Shaw Atherosclerotic Plaque Imaging: Contemporary Role in Preventive Cardiology Arch Intern Med, November 14, 2005; 165(20): 2345 - 2353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A.C. Lima, M. Y. Desai, H. Steen, W. P. Warren, S. Gautam, and S. Lai Statin-Induced Cholesterol Lowering and Plaque Regression After 6 Months of Magnetic Resonance Imaging-Monitored Therapy Circulation, October 19, 2004; 110(16): 2336 - 2341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Sidhu, Z. Kaposzta, H. S. Markus, and J. C. Kaski Effect of Rosiglitazone on Common Carotid Intima-Media Thickness Progression in Coronary Artery Disease Patients Without Diabetes Mellitus Arterioscler Thromb Vasc Biol, May 1, 2004; 24(5): 930 - 934. [Abstract] [Full Text]
|
|
|
|
|
|
P. R. W. de Sauvage Nolting, E. de Groot, A. H. Zwinderman, R. J. A. Buirma, M. D. Trip, and J. J. P. Kastelein Regression of Carotid and Femoral Artery Intima-Media Thickness in Familial Hypercholesterolemia: Treatment With Simvastatin Arch Intern Med, August 11, 2003; 163(15): 1837 - 1841. [Abstract] [Full Text] [PDF]
|
|